In patients with diabetic kidney disease (DKD), the estimated glomerular filtration rate (eGFR) or creatinine clearance rate (Ccr) is always used as an index of decline in renal function. However, there are few animal models of DKD that could be used to evaluate renal function based on GFR or Ccr. For this reason, it is desirable to develop animal models to assess renal function, which could also be used for the evaluation of novel therapeutic agents for DKD. Therefore, we aimed to develop such animal model of DKD by using spontaneously hypertensive rat (SHR)/NDmcr-cp (cp/cp) rats with the characteristics of obese type 2 diabetes and metabolic syndrome. As a result, we have found that unilateral nephrectomy (UNx) caused a chronic Ccr decline, development of glomerular sclerosis, tubular lesions, and tubulointerstitial fibrosis, accompanied by renal anemia. Moreover, losartan-mixed diet suppressed the Ccr decline in UNx-performed SHR/NDmcr-cp rats (UNx-SHR/cp rats), with improvement in renal anemia and histopathological changes. These results suggest that UNx-SHR/cp rats could be used as a DKD model for evaluating the efficacy of therapeutic agents based on suppression of renal function decline.

Laboratory of Animal Physiology and Functional Anatomy Graduate School of Agriculture Kyoto University Kyoto Japan

Zobrazit více v PubMed

KDIGO Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99:S1–S87. doi: 10.1016/j.kint.2020.11.003. PubMed DOI

Kota SK, Meher LK, Jammula S, Kota SK, Modi KD. ACE inhibitors or ARBs for diabetic nephropathy: the unrelenting debate. Diabetes Metab Syndr. 2012;6:215–217. doi: 10.1016/j.dsx.2012.08.005. PubMed DOI

Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R, Investigators RS. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int. 2003;63:1499–1507. doi: 10.1046/j.1523-1755.2003.00885.x. PubMed DOI

Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P Irbesartan in Patients with Type D, Microalbuminuria Study G. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–878. doi: 10.1056/NEJMoa011489. PubMed DOI

Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjostrom CD, Toto RD, Langkilde AM, Wheeler DC Committees D-CT Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383:1436–1446. doi: 10.1056/NEJMoa2024816. PubMed DOI

Tuttle KR, Brosius FC, 3rd, Cavender MA, Fioretto P, Fowler KJ, Heerspink HJL, Manley T, McGuire DK, Molitch ME, Mottl AK, Perreault L, Rosas SE, Rossing P, Sola L, Vallon V, Wanner C, Perkovic V. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. Am J Kidney Dis. 2021;77:94–109. doi: 10.1053/j.ajkd.2020.08.003. PubMed DOI

Shinozaki Y, Katayama Y, Yamaguchi F, Suzuki T, Watanabe K, Uno K, Tsutsui T, Sugimoto M, Shinohara M, Miyajima K, Ohta T. Salt loading with unilateral nephrectomy accelerates decline in glomerular filtration rate in the hypertensive, obese, type 2 diabetic SDT fatty rat model of diabetic kidney disease. Clinical and experimental pharmacology & physiology. 2022;49:492–500. doi: 10.1111/1440-1681.13621. PubMed DOI

Chander PN, Gealekman O, Brodsky SV, Elitok S, Tojo A, Crabtree M, Gross SS, Goligorsky MS. Nephropathy in Zucker diabetic fat rat is associated with oxidative and nitrosative stress: prevention by chronic therapy with a peroxynitrite scavenger ebselen. J Am Soc Nephrol. 2004;15:2391–2403. doi: 10.1097/01.ASN.0000135971.88164.2C. PubMed DOI

Tesch GH, Allen TJ. Rodent models of streptozotocin-induced diabetic nephropathy. Nephrology. 2007;12:261–266. doi: 10.1111/j.1440-1797.2007.00796.x. PubMed DOI

Maekawa M, Maekawa T, Sasase T, Takagi K, Takeuchi S, Kitamoto M, Nakagawa T, Toyoda K, Konishi N, Ohta T, Yamada T. Pathophysiological analysis of uninephrectomized db/db mice as a model of severe diabetic kidney disease. Physiological research. 2022;71:209–217. doi: 10.33549/physiolres.934784. PubMed DOI PMC

Sano R, Ishii Y, Yamanaka M, Yasui Y, Kemmochi Y, Kuroki F, Sugimoto M, Fukuda S, Sasase T, Miyajima K, Nakae D, Ohta T. Glomerular hyperfiltration with hyperglycemia in the spontaneously diabetic Torii (SDT) fatty rat, an obese type 2 diabetic model. Physiological research. 2021;70:45–54. doi: 10.33549/physiolres.934533. PubMed DOI PMC

Ohtomo S, Izuhara Y, Nangaku M, Dan T, Ito S, van Ypersele de Strihou C, Miyata T. Body weight control by a high-carbohydrate/low-fat diet slows the progression of diabetic kidney damage in an obese, hypertensive, type 2 diabetic rat model. Journal of obesity. 2010:2010. doi: 10.1155/2010/136502. PubMed DOI PMC

Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol. 2017;12:2032–2045. doi: 10.2215/CJN.11491116. PubMed DOI PMC

Nangaku M, Izuhara Y, Usuda N, Inagi R, Shibata T, Sugiyama S, Kurokawa K, van Ypersele de Strihou C, Miyata T. In a type 2 diabetic nephropathy rat model, the improvement of obesity by a low calorie diet reduces oxidative/carbonyl stress and prevents diabetic nephropathy. Nephrol Dial Transplant. 2005;20:2661–2669. doi: 10.1093/ndt/gfi096. PubMed DOI

Cohen MP, Lautenslager GT, Shearman CW. Increased urinary type IV collagen marks the development of glomerular pathology in diabetic d/db mice. Metabolism. 2001;50:1435–1440. doi: 10.1053/meta.2001.28074. PubMed DOI

Gartner K. Glomerular hyperfiltration during the onset of diabetes mellitus in two strains of diabetic mice (c57bl/6j db/db and c57bl/ksj db/db) Diabetologia. 1978;15:59–63. doi: 10.1007/BF01219330. PubMed DOI

Katsuda Y, Kemmochi Y, Maki M, Sano R, Toriniwa Y, Ishii Y, Miyajima K, Kakimoto K, Ohta T. Effects of unilateral nephrectomy on renal function in male Spontaneously Diabetic Torii fatty rats: a novel obese type 2 diabetic model. J Diabetes Res. 2014;2014:363126. doi: 10.1155/2014/363126. PubMed DOI PMC

O’Sullivan J, Finnie SL, Teenan O, Cairns C, Boyd A, Bailey MA, Thomson A, Hughes J, Benezech C, Conway BR, Denby L. Refining the Mouse Subtotal Nephrectomy in Male 129S2/SV Mice for Consistent Modeling of Progressive Kidney Disease With Renal Inflammation and Cardiac Dysfunction. Front Physiol. 2019;10:1365. doi: 10.3389/fphys.2019.01365. PubMed DOI PMC

Heyman SN, Khamaisi M, Zorbavel D, Rosen S, Abassi Z. Role of Hypoxia in Renal Failure Caused by Nephrotoxins and Hypertonic Solutions. Seminars in nephrology. 2019;39:530–542. doi: 10.1016/j.semnephrol.2019.10.003. PubMed DOI

Suzuki N. Erythropoietin gene expression: developmental-stage specificity, cell-type specificity, and hypoxia inducibility. The Tohoku journal of experimental medicine. 2015;235:233–240. doi: 10.1620/tjem.235.233. PubMed DOI

Bobulescu IA. Renal lipid metabolism and lipotoxicity. Current opinion in nephrology and hypertension. 2010;19:393–402. doi: 10.1097/MNH.0b013e32833aa4ac. PubMed DOI PMC

Afshinnia F, Nair V, Lin J, Rajendiran TM, Soni T, Byun J, Sharma K, Fort PE, Gardner TW, Looker HC, Nelson RG, Brosius FC, Feldman EL, Michailidis G, Kretzler M, Pennathur S. Increased lipogenesis and impaired beta-oxidation predict type 2 diabetic kidney disease progression in American Indians. JCI insight. 2019:4. doi: 10.1172/jci.insight.130317. PubMed DOI PMC

Thomas MC. Glycemic exposure, glycemic control, and metabolic karma in diabetic complications. Advances in chronic kidney disease. 2014;21:311–317. doi: 10.1053/j.ackd.2014.03.004. PubMed DOI

Roy S, Sala R, Cagliero E, Lorenzi M. Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory. Proc Natl Acad Sci U S A. 1990;87:404–408. doi: 10.1073/pnas.87.1.404. PubMed DOI PMC

Cooper ME, El-Osta A. Epigenetics: mechanisms and implications for diabetic complications. Circulation research. 2010;107:1403–1413. doi: 10.1161/CIRCRESAHA.110.223552. PubMed DOI

Michel O, Heudes D, Lamarre I, Masurier C, Lavau M, Bariety J, Chevalier J. Reduction of insulin and triglycerides delays glomerulosclerosis in obese Zucker rats. Kidney Int. 1997;52:1532–1542. doi: 10.1038/ki.1997.483. PubMed DOI

Tuttle KR, Cherney DZ Diabetic kidney disease task force of the American Society of N. sodium glucose cotransporter 2 inhibition heralds a call-to-action for diabetic kidney disease. Clin J Am Soc Nephrol. 2020;15:285–288. doi: 10.2215/CJN.07730719. PubMed DOI PMC

Noshahr ZS, Salmani H, Khajavi Rad A, Sahebkar A. Animal models of diabetes-associated renal injury. J Diabetes Res. 2020;2020:9416419. doi: 10.1155/2020/9416419. PubMed DOI PMC

Soler MJ, Riera M, Batlle D. New experimental models of diabetic nephropathy in mice models of type 2 diabetes: efforts to replicate human nephropathy. Exp Diabetes Res. 2012;2012:616313. doi: 10.1155/2012/616313. PubMed DOI PMC

Patel V, Joharapurkar A, Jain M. Role of mineralocorticoid receptor antagonists in kidney diseases. Drug development research. 2021;82:341–363. doi: 10.1002/ddr.21760. PubMed DOI

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE Investigators E-RO. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373:2117–2128. doi: 10.1056/NEJMoa1504720. PubMed DOI

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, Group CPC. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657. doi: 10.1056/NEJMoa1611925. PubMed DOI